H.C. Wainwright analyst Brandon Folkes assumed coverage of Collegium Pharmaceutical (COLL) with a Buy rating and $44 price target The firm views the growth potential of Jornay PM as as underappreciated. Jornay has “rapidly emerged as the company’s lead growth driver,” the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical Reports Strong Q2 2025 Results
- Collegium Pharmaceuticals Reports Strong Earnings and Growth
- Collegium Pharmaceutical’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Collegium Pharmaceutical Reports Record Q2 2025 Revenue
- Collegium Pharmaceutical reports Q2 adjusted EPS $1.68, consensus $1.85